Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial
about
The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)Aspirin and clopidogrel resistance: consideration and managementPharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesPharmacological antithrombotic adjuncts to percutaneous coronary intervention.Antiplatelet drugs in cardiological practice: established strategies and new developmentsBalancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome.Platelet interactions as therapeutic targets for prevention of atherothrombosis.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Cangrelor: a novel P2Y12 receptor antagonist.P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Platelet P2Y12 receptor inhibition by thienopyridines: status and future.Cangrelor: a review on its mechanism of action and clinical development.Personalized antiplatelet therapy for coronary artery disease patients: is this the future?Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.Update on the clinical development of cangrelor.Antiplatelet therapy in acute coronary syndromes.Review: Antiplatelet drugs: what comes next?Antiplatelet therapy and vascular disease: an update.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery.Emerging antiplatelet agents, differential pharmacology, and clinical utility.Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.Modern antiplatelet agents in coronary artery disease.Pharmacotherapy for the reduction of stent thrombosis.Emerging antithrombotic drugs for acute coronary syndrome.Cangrelor: a review on pharmacology and clinical trial development.Cangrelor for treatment of arterial thrombosis.Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).Use of novel antiplatelet agents in acute coronary syndromes.The progress in the research of antiplatelet agents (1995-2017).A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
P2860
Q24187718-D8375B85-F80F-4718-BC09-A70D02AC7D8FQ24197708-6A3EDFAA-DFDF-4363-B895-52988716C36AQ28200610-DE50DCE2-BCD3-48F2-ACCF-45BD5F2D7857Q33685876-7E193771-1D4B-49EC-9ADE-A030E43CD972Q33902628-BDB91D7E-EA16-4FB4-9F15-D87474FE36A2Q34771381-426E5109-8812-428B-BFE8-2D29CAB347F5Q34994015-97F0168C-0A16-49A3-B84F-8768D0EACE33Q35569714-0CE7499D-E4DF-4323-A03E-56E3F70127BAQ35752611-B96F86FE-C98B-4C58-A2C0-40D3A280D758Q36787291-1E7E3961-2699-4E7E-A6B9-E20AA6527D80Q36835862-48E98C5B-23AC-463D-AD92-8D4A335514A8Q37311337-2E260B25-D9E5-4691-B709-C56C0CC7B3EDQ37486621-2D6B81FD-3670-4626-885B-8447AEAB7330Q37550156-2DC605FF-2F0C-4BCA-8550-134BC77F7D56Q37551923-4CA5B044-0655-4A1C-9E0F-32CE5C2F625BQ37562606-6B43E9EB-8F77-410E-9256-26F03E860307Q37579228-78B435DD-F801-477E-B258-2D7A89CD64C8Q37611039-E6EB73F9-5541-43BD-A140-C3F3EC90ADC1Q37642822-585472B9-D829-4644-9D72-867AF6C20946Q37714189-0D9E5C39-6462-4A88-A574-9156E9B30E76Q37752222-9F9C0E08-C44D-4B49-B173-EB801A31C331Q37776511-F88B7BAD-C28F-4F6D-87F6-7CD1117EEBFAQ37798110-B8AECCAF-CF1C-48CA-B1D0-32CD6195038AQ37809630-D98E3743-39FC-4F89-BB7C-036EA008DCD1Q37838100-3CD020E5-FBD8-418F-9E98-F485D0FEA7C0Q37923969-4FCECA9C-19CE-4DB8-AEDE-D35D4C76301BQ37925007-67E0B633-6604-44D4-92C7-BEC035391896Q37937717-7C8080C6-622E-479B-BFF7-DF294DB493D5Q37979178-179B9055-2EE3-46BF-A5F9-0736C6D06263Q38037672-5B54CC61-4E50-41E1-A737-088F57D18C85Q38063289-AA153F6F-AD0B-4D23-BE19-88A9BAB4490BQ38101963-60ADCFBF-057D-4145-AB61-449F841A998FQ38121144-CF5EE010-943D-4CB4-B593-E2FCED072ECFQ38153779-0814EC3C-CF06-49EB-82E0-B28C5FF41C41Q38183489-6A638438-EC42-464C-8BBC-804987125AA5Q38197732-F686CB09-CB86-4994-A826-466E634457BDQ38216215-C1CEAA1A-58BA-420B-9AE8-14C0980BDD83Q38348649-EE4CF0A6-0FD3-4775-BDD6-7EA1A2F98EF6Q38669003-AD9732E8-351D-4B5E-9778-38F79FD11994Q38672923-6BCF7AE6-9F80-4C6F-8D62-D0BC6702FF34
P2860
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Initial experience with an int ...... o- and active-controlled trial
@ast
Initial experience with an int ...... o- and active-controlled trial
@en
Initial experience with an int ...... o- and active-controlled trial
@nl
type
label
Initial experience with an int ...... o- and active-controlled trial
@ast
Initial experience with an int ...... o- and active-controlled trial
@en
Initial experience with an int ...... o- and active-controlled trial
@nl
prefLabel
Initial experience with an int ...... o- and active-controlled trial
@ast
Initial experience with an int ...... o- and active-controlled trial
@en
Initial experience with an int ...... o- and active-controlled trial
@nl
P2093
P921
P1476
Initial experience with an int ...... o- and active-controlled trial
@en
P2093
Adam B Greenbaum
Cindy L Grines
Dean J Kereiakes
Donna R Grogan
Ian C Gilchrist
Jane Clegg
Jill E Stankowski
John A Bittl
Richard C Becker
W Douglas Weaver
P304
689.e1-689.e10
P356
10.1016/J.AHJ.2005.11.014
P407
P577
2006-03-01T00:00:00Z